Acquisition strengthens firm’s dermatology focus.



Valeant Pharmaceuticals acquired DermaTech for approximately AU$19 million ($12.6 million).


Earlier this year, under the direction of a new CEO, Valeant revised its business strategy to, among other things, build on its strengths in neurology and dermatology.  DermaTech specializes in the development, production, and distribution of products to address common dermatological conditions; its current annualized net sales total approximately $6.9 million.








This site uses Akismet to reduce spam. Learn how your comment data is processed.